OncoCyte (OncoCyte) Retained Earnings : $-289.88 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is OncoCyte Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. OncoCyte's retained earnings for the quarter that ended in Dec. 2023 was $-289.88 Mil.

OncoCyte's quarterly retained earnings declined from Jun. 2023 ($-265.98 Mil) to Sep. 2023 ($-272.47 Mil) and declined from Sep. 2023 ($-272.47 Mil) to Dec. 2023 ($-289.88 Mil).

OncoCyte's annual retained earnings declined from Dec. 2021 ($-187.77 Mil) to Dec. 2022 ($-260.68 Mil) and declined from Dec. 2022 ($-260.68 Mil) to Dec. 2023 ($-289.88 Mil).

OncoCyte Retained Earnings Historical Data

The historical data trend for OncoCyte's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Retained Earnings Chart

OncoCyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-93.75

-123.68

-187.77

-260.68

-289.88

OncoCyte Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Retained Earnings	Get a 7-Day Free Trial															-260.68	-257.64	-265.98	-272.47	-289.88

OncoCyte Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

OncoCyte (NAS:OCX) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

OncoCyte (OncoCyte) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OncoCyte Corp (NAS:OCX) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

15 Cushing, Irvine, CA, USA, 92618

Website

https://www.oncocyte.com

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States.

Executives

John Peter Gutfreund	other: Former Director	767 5TH AVENUE, 44TH FLOOR, NEW YORK NY 10153
Alfred D Kingsley	director	150 E 57TH STREET, NEW YORK NY 10022
Pura Vida Investments, Llc	10 percent owner	512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Broadwood Partners Lp	10 percent owner	BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019
Andrew Arno	director	C/O MERRIMAN CURHAN FORD GROUP, INC., 600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108
Josh Riggs	officer: Interim CEO	15 CUSHING, IRVINE CA 92618
Lou Silverman	director
James Yang Liu	officer: Controller, PAO	C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
Andrew J. Last	director	3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Jennifer L. Carter	director	C/O DFP SPONSOR LLC, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Ronald Asbury Andrews	director	5791 VAN ALLEN WAY, CARLSBAD CA 92008
Melinda Griffith	director	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Anish M. John	officer: SVP, Finance, and Interim CFO	C/O ONCOCYTE CORPORATION,, 15 CUSHING, IRVINE CA 92618
Li Yu	officer: VP Cntrllr/Prncpl Acctng Offcr	120 NEWPORT CENTER DRIVE., NEWPORT BEACH CA 92660
Efrem Kamen	10 percent owner	C/O PURA VIDA INVESTMENTS, LLC, 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011